Table 4.
Summary of Adverse Events During Induction and Maintenance for All Patients (those with follicular lymphoma and with nonfollicular lymphoma)*
| Patients | Induction |
Maintenance |
||
|---|---|---|---|---|
| Obinutuzumab (n = 87) No. (%) | Rituximab (n = 86) No. (%) | Obinutuzumab (n = 73) No. (%) | Rituximab (n = 72) No. (%) | |
| ≥ 1 AE† | 75 (86) | 58 (67) | 61 (84) | 58 (81) |
| Grade 3 to 4 AE | 15 (17) | 13 (15) | 13 (18) | 15 (21) |
| SAE | 5 (6) | 7 (8) | 8 (11) | 6 (8) |
| Grade 3 to 4 IRR | 10 (11) | 4 (5) | 0 | 0 |
| Grade 3 to 4 infection | 0 | 4 (5) | 3 (4) | 2 (3) |
| Grade 3 to 4 neutropenia | 0 | 1 (1) | 3 (4) | 6 (8) |
Abbreviations: AE, adverse event; IRR, infusion-related reaction; SAE, serious adverse event.
*
Unless otherwise noted, the AE proportions between the two treatment arms were not significantly different (Fisher's exact P [two-sided] > .05).
†
Fisher's exact P (two-sided) = .03.